GSK is beefing up its pipeline with two new deals that should open up combination possibilities in cancer and build on its recent progress in oncology. It has forged an agreement with DualityBio on an antibody-drug conjugate (ADC) product and with Rgenta Therapeutics to use its RNA-targeting small molecule platform.
GSK Expands Its Oncology Options With DualityBio And Rgenta Deals
The company is keeping up a flow of deals in oncology, opening up access to a range of new modalities and potential future combinations with two new tie-ups.
More from Deals
• By
The latest in a long line of restructuring moves will see Sumitomo Pharma selling its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus